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Abstract: The monoclonal chimeric anti-CD20 antibody, rituximab, has considerably 
improved therapeutic outcome in B-cell chronic lymphocytic leukemia. Rituximab has limited 
clinical activity when used as a single agent. The combination of the monoclonal antibody 
with fludarabine-based regimens clearly demonstrated, in Phase II and randomized trials, an 
increase in clinical efficacy in previously untreated and pretreated patients. Furthermore the 
addition of rituximab enabled the eradication of minimal residual disease, which is correlated 
with the prognosis in a high proportion of patients. Although the combination of rituximab with 
fludarabine-based regimens increased myelosuppression and immunosuppression, incidence of 
infections did not increase. The benefit of adding rituximab to other purine analogs or other 
chemotherapeutic combination regimens has also been explored. Moreover there could be a role 
for achieving better quality of responses with the combination of different monoclonal antibodies, 
considering that they target different antigens and exert different mechanism of action. Although 
the role of rituximab as maintenance therapy in low grade non-Hodgkin’s lymphomas has been 
determined, the benefit and optimal schedule in chronic lymphocytic leukemia are still under 
investigation. This review brings together knowledge of the pharmacokinetics, mechanism of 
action and clinical use of rituximab in chronic lymphocytic leukemia.
Keywords: rituximab, B-cell chronic lymphocytic leukemia, first-line treatment, refractory/
relapsed
Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in Western 
countries, with an annual incidence of 3 to 5 cases per 100,000.1 The disease is rare 
in people younger than 50 years, but incidence rises fairly rapidly above this age. The 
median age at diagnosis, according to Surveillance, Epidemiology and End Results 
(SEER), is 70 years for men and 74 years for women.1
Overall survival (OS) rate in CLL after diagnosis ranges from less than 2 to more 
than 15 years, with a median of 9 years, because the clinical course is extremely 
  variable. A third of patients never need treatment and have long survival, in another 
third an initial indolent phase is followed by disease progression, and the remaining 
third exhibit aggressive disease at onset and need immediate treatment.2
Although clinical stagings proposed in the early 1980s by Binet et al3 and Rai et al4 
are still widely used as prognostic factors in CLL, these systems do not enable 
  identification of patients in early stages who are likely to progress and those in whom 
the disease will remain stable for many years.
In recent years, several biological markers – mutation status of the immunoglobu-
lin heavy chain variable chain (IgVH), expression of ZAP-70, expression of CD38, OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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chromosome abnormalities identified by fluorescence in situ 
hybridization (FISH) analysis, and P53 mutations – have 
been identified as important prognostic factors.5–10 These 
factors, as well as other historical serological parameters such 
as beta2-microglobulin,11 proved to be useful in predicting 
which patients would develop progressive disease. Further-
more they may provide prognosis assessment for response 
to treatment, response duration and survival.
In routine clinical practice, therapy should not be initiated 
in patients who have asymptomatic CLL, including those 
with Rai stage 0 or Binet stage A, until disease progression 
or unless disease-related symptoms are evident. The observa-
tion that early treatment in asymptomatic patients does not 
prolong survival is supported by a meta-analysis.12 In seven 
trials including 2048 early-stage patients randomly allocated 
to immediate or deferred treatment with chlorambucil (with 
or without prednisolone) no benefit for either treatment group 
was observed.
However the potential benefit of an early intervention 
therapy according to prognostic factors and novel agents, 
including monoclonal antibodies, requires further study. 
Current trials are ongoing in Europe and in the United States 
(US) to re-address this issue using more efficient treatments 
and considering patients with high-risk features.
Widely accepted guidelines for the initiation of chemo-
therapy in CLL have been proposed by the National Cancer 
Institute Sponsored Working Group13 and have been recently 
reviewed by the International Workshop on Chronic Lympho-
cytic Leukemia (IWCLL).14 According to these guidelines 
the criteria for initiation of therapy may not be identical for 
routine clinical practice and for clinical trials.
Despite improvement in therapy, CLL remains incurable 
with standard therapy. Patients inevitably relapse, becoming 
increasingly refractory to treatment and often acquiring high-
risk chromosomal abnormalities. In the past two decades the 
introduction of purine analogs, most notably fludarabine, has 
had an important effect on CLL management.15 Fludarabine 
has demonstrated greater efficacy than chlorambucil or CAP 
(cyclophosphamide, doxorubicin and prednisone) in obtain-
ing higher response rates, complete remission (CR) rates and 
progression-free survival (PFS).16–18 The advantages were 
greater when purine nucleoside analogs were combined with 
cyclophosphamide and/or mitoxantrone.19–21
However studies with purine analogs-based chemotherapy 
failed to show an advantage in terms of OS.22 The same 
observation can be applied when considering results obtained 
with other chemotherapeutic agents administered alone or in 
combination treatments.
A recent advance in the treatment of CLL is the 
  development of monoclonal antibodies directed against 
specific proteins expressed by CLL B-cells. Both alem-
tuzumab and rituximab, the two antibodies with the most 
clinical value in CLL, were shown to be active when used in 
monotherapy.23,24 The preclinical evidence of the synergistic 
effect between monoclonal antibodies and chemotherapeutic 
agents25,26 and the need for new association treatments, based 
on drugs with different mechanisms of actions possibly 
without adding major toxicities, prompted the investigation 
of immunochemotherapeutic regimens. Treatment strate-
gies including monoclonal antibodies not only improved 
response rates, but also achieved better quality of responses, 
with minimal residual disease (MRD) being eradicated in a 
significant proportion of patients.27–29
The achievement of MRD, as determined by flow-  cytometry 
or polymerase chain reaction (PCR)-based amplification of 
the IgVH rearrangement, is correlated with an improvement 
in time to retreatment and PFS.27–31 In 2005, Moreton et al 
first correlated the eradication of MRD with an improvement 
of OS after alemtuzumab monotherapy treatment in relapsed 
CLL patients.32 However, even if immunochemotherapy 
has eradicated MRD, patients will eventually relapse, as 
published trials have failed to demonstrate a plateau of PFS 
and OS curves. Although eradication of MRD may improve 
prognosis, prospective clinical trials are needed to define 
whether additional treatment administered to eradicate MRD 
provides significant benefit to clinical outcome.
To address this issue, MRD negativity has been adopted 
as a recommended trial endpoint in the recently updated 
diagnostic and treatment guidelines of the IWCLL working 
group.14
Allogeneic stem cell transplantation offers the possibility 
of a definite cure, but despite recent developments, such as 
reduced intensity conditioning and better supportive care, it 
is still associated with significant morbidity and mortality. 
However, in patients carrying del17p, requiring treatment, an 
allogeneic transplant should be considered as a therapeutic 
option that may induce long-lasting remissions.33
The current review brings together knowledge of the 
pharmacokinetics, mechanisms of action, and clinical use 
of rituximab in CLL.
Mechanism of action, 
pharmacokinetics of rituximab
Rituximab is a chimeric human/mouse Ig1-kappa antibody 
that targets the CD20 antigen. The chimeric structure of 
rituximab incorporates murine variable regions and human OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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constant kappa and Fc regions to diminish the development 
of anti-mouse immunoglobulin antibody side effects and 
possibly resistance.34
CD20, a cell-surface glycoprotein, is a calcium channel 
that interacts with the B-cell immunoglobulin receptor com-
plex. CD20 is tightly restricted to the B-cell lineage and is 
expressed on the cell surface of more than 95% of normal and 
malignant B-cells, excluding stem cells and plasma cells.35 
However there are several differences in CD20 expression 
between B-cell malignancies. In contrast to B-cell lympho-
mas, which uniformly express CD20 strongly, relatively low 
levels of CD20 are typically expressed in CLL.36
Rituximab exerts its anticancer effects through more than 
one mechanism of action. The predominant   mechanisms 
of rituximab-induced cell death are proposed to be the 
result of antibody-dependent cell-mediated cytotoxicity 
(ADCC), complement-dependent cytotoxicity (CDC), and 
apoptosis.37–41
The relative importance of these mechanisms may differ 
between CLL and B-cell non-Hodgkin’s lymphomas (NHL).
ADCC seems to be the predominant mechanism for 
the clearance of neoplastic cells in lymphomas, and Fc-γ 
receptors are critical for the in vivo actions of rituximab. 
The difference in response rates among lymphoma patients 
according to Fc-γ RIIIa polymorphisms supports the impor-
tance of ADCC in the in vivo actions of rituximab.42 In con-
trast, in CLL Fc-γ RIIIa polymorphisms are not predictive 
for response.43 In vitro studies with rituximab have shown 
CDC to be more rapid and effective at inducing cell death 
than ADCC or apoptosis,40,41 particularly for blood-borne 
diseases, such as the leukemic-phase of B-cell NHL, includ-
ing CLL, in which access to complement may be enhanced. 
Complement activation may be important, as increased 
expression of complement inhibitors CD55 and CD59 
resulted in resistance to rituximab in B-NHL cell lines and 
CLL cells.44,45 However caspase-3 activation and induction 
of apoptosis, using a pathway similar to that of fludarabine 
and other chemotherapeutic agents, appear to play a more 
important role in CLL than in B-cell NHL.44,46,47
In addition to the efficacy of rituximab in inducing a 
proapoptotic signal via the cell surface target structure, 
several studies have pointed out the activity of rituximab in 
promoting cellular responses against tumors. Selenko et al 
demonstrated in vitro that the monoclonal anti-CD20 anti-
body promotes uptake and cross-presentation of lymphoma 
cell-derived peptides by antigen-presenting dendritic cells 
inducing maturation of dendritic cells, and allows the genera-
tion of specific cytotoxic T-cells that may have a long-lasting 
protective effect.48,49 Although this mechanism remains to 
be proved in vivo, the evidence of tardive and prolonged 
responses to rituximab treatment suggests that there is the 
potential for long-lasting antitumor protection.
Rituximab as a single agent
Single-dose Phase I trials showed the antibody to be well 
tolerated, with a half-life of 4 days.50 Multiple-dose sched-
ules were developed and the Phase II trials explored a four-
dose schedule.51,52 In the US Phase II trial 166 patients with 
relapsed low-grade lymphomas received rituximab at a dose 
of 375 mg/m2 weekly for four consecutive weeks.52 The 
subgroup of 33 patients with small lymphocytic lymphoma 
(SLL), the tissue counterpart of CLL, achieved a significantly 
lower response rate than those with follicular lymphoma 
(12% vs 58%; P , 0.01). Subsequent studies in relapsed CLL 
with rituximab administered at a dose of 375 mg/m2 weekly 
for 4 weeks also showed a lower response rate than usually 
seen in NHL, with almost all responses being categorized as 
partial remissions (Table 1).51,53–60
Two studies explored the efficacy of rituximab in first-
line treatment.59,60 Hainsworth et al achieved an initial overall 
response rate (ORR) of 51% (4% CR) after initial standard 
rituximab regimen, increasing to 70% after maintenance 
therapy in CLL/SLL patients.59 A high ORR (90%, 9% CR), 
was also reported by Thomas et al in 21 CLL patients with Rai 
stage 0, I, II disease and elevated beta2-microglobulin level 
without other indications of therapy.60 Although rituximab 
used in first-line treatment was shown to be more effective 
than in the setting of relapsed/refractory patients, the drug 
in CLL/SLL is still less active than in follicular lymphomas. 
Furthermore, better quality of responses and more prolonged 
PFS can be obtained with fludarabine in monotherapy, albeit 
with more substantial toxicity.61
Several explanations have been considered for the 
reduced responsiveness of CLL/SLL to monoclonal antibody 
treatment. CD20 expression in CLL/SLL is significantly 
lower than in other types of NHL, which may affect the 
degree of antibody binding.37 However Perz et al could not 
identify a correlation between CD20 expression and efficacy 
of   rituximab treatment.62 Another mechanism could be the 
rapid clearance of the antibody from the circulation due to 
the high number of circulating cells in CLL, which may 
give a lower serum concentration. Furthermore, because 
high levels of soluble CD20 have been demonstrated in 
plasma of patients with CLL,63 it is theoretically possible that 
  circulating CD20 may deplete the concentration of rituximab 
available for binding to the tumor cells.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Whatever the reason for the poorer responses, pharma-
cokinetic studies conducted in relapsed refractory NHL 
showed markedly lower levels of circulating rituximab in the 
serum of patients with Working Formulation A disease.52
The standard regimen of 375 mg/m2 weekly for 4 weeks 
was established for the treatment of NHL on the basis of effi-
cacy and maximum tolerated dose in a dose escalation study; 
however patients receiving higher dosages of the monoclonal 
antibody showed no evidence of dose-limiting toxicity.64 
This was the rationale for increasing dosing of rituximab 
in CLL in order to maintain high antibody concentrations 
in serum and possibly overcome its rapid clearance by the 
large number of circulating CLL cells.
Both dose-intense and dose-intensity strategies have been 
considered in previously treated patients.
O’Brien et al designed a dose escalation study with an 
initial infusion of 375 mg/m2 followed by three further esca-
lating doses ranging from 500 mg to 2250 mg/m2.57 Results 
of this study showed that responses were strongly correlated 
with the dose administered: 21% of responses with the dose 
of 500 mg/m2 compared with 75% after the administration of 
the higher dose of  2250 mg/m2. Toxicity in the dosage range 
of 500 mg up to 1500 mg/m2 was very uncommon, and maxi-
mum tolerated dose was  2250 mg/m2. Infusion-related events 
were mostly associated with the first infusion of 375 mg/m2.
In another study of dose intensity, Byrd et al increased the 
frequency of the standard rituximab dose to 3 times per week. 
The same regimen was applied in six untreated patients, and 
an ORR of 83% was obtained.58
Even if these studies indicated that increased doses of 
rituximab are effective, median time to progression was of 
short duration in both studies (8 and 11 months, respectively). 
Furthermore these schedules are not applicable in routine 
medical practice and, therefore, other strategies to increase 
the efficacy of rituximab have been considered.
Rituximab in combination  
with purine analogs
Rituximab plus fludarabine
Rituximab enhances the activity of purine analog-based 
therapies and has been incorporated into immunochemo-
therapy regimens.39
In vitro studies have demonstrated that apoptosis is 
enhanced in an additive or synergistic manner when ritux-
imab is combined with chemo- or immunotherapy molecules. 
Cultured CLL and NHL cells treated with 10 µg/mL ritux-
imab lessened the inhibitory concentration needed by various 
chemotherapeutic agents to induce apoptosis via increased 
p53 and activated caspase-3, -7, and -8, irrespective of the 
addition of exogenous complement proteins.65,66 Rituximab, 
by downmodulating the expression of the antiapoptotic 
protein bcl-2, may sensitize leukemia cells to fludarabine-
induced apoptosis.25 Furthermore, fludarabine downmodu-
lates expression of complement resistance proteins CD46, 
CD56, and CD59 on malignant B-cells and renders them 
more susceptible to rituximab-induced CDC.45
Fludarabine is one of the most commonly used chemo-
therapeutic agents in CLL, having an independent single-
agent activity and no overlapping toxicity with rituximab. 
As the purine analog synergizes in vitro with rituximab, most 
studies of immunochemotherapy have focused on regimens of 
combinations of rituximab with fludarabine or fludarabine.
The Cancer and Leukemia Group B (CALGB)   conducted 
a randomized Phase II clinical trial to determine the ideal 
administration schedule of rituximab plus fludarabine 
in untreated patients (CALGB 9712).67 Patients were 
Table 1 Rituximab as a single agent
Authors No. evaluable pts Disease status Rituximab schedule Response 
winkler et al53 9 Pretreated 375 mg/m2/w iv for 4 weeks 1 (11%) PR
Nguyen et al54 15 Pretreated 375 mg/m2/w iv for 4 weeks 1 (7%) PR
Foran et al51 29 Pretreated 375 mg/m2/w iv for 4 weeks 4 (14%) PR 
Huhn et al55 28 Pretreated 375 mg/m2/w iv for 4 weeks 7 (25%) PR
itala et al56 23 Pretreated 375 mg/m2/w iv for 4 weeks 8 (35%) PR
O’Brien et al57 24 
7 
8
Pretreated 375 mg/m2 iv wk 1, 500–825 mg/m2 iv weeks 2,3,4
375 mg/m2 iv wk 1, 1000–1500 mg/m2 iv weeks 2,3,4
375 mg/m2 iv wk 1, 2250 mg/m2 iv weeks 2,3,4
5 (21%) PR
3 (43%) PR
6 (75%) PR
Byrd et al58 29 Pretreated
Untreated
250 mg/m2/ tiw iv for 4 weeks
375 mg/m2/ tiw iv for 4 weeks
14 (48%) PR
1 (4%) CR
Hainsworth et al59 43 Untreated  375 mg/m2/w iv for 4 weeks 22 (51%) OR
2 (4%) CR
Thomas et al60 21 Untreated 375 mg/m2/w iv for 4 weeks 19 (90%) OR
2 (9%) CR
Abbreviations: pts, patients; w, weekly; iv, intravenous; PR, partial response; CR, complete response; OR, overall response; tiw, 3 times a week.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  randomized to receive one course every 4 weeks for 6 months 
of concurrent fludarabine and rituximab followed by four 
rituximab consolidation courses or sequential treatment of 
fludarabine alone followed by four infusions of rituximab 
as consolidation.
The concurrent schedule was shown to be more effective 
than the sequential in achieving a higher CR rate (47% vs 
28%), while the ORR (90% vs 77%) and PFS did not differ sig-
nificantly between the two groups. Recently updated long-term 
follow-up of patients enrolled on CALGB 9712 demonstrated 
extended OS and PFS, with an estimated 17% of responders 
still in remission after 8 years.68 The results of this study were 
retrospectively compared with the outcome of patients treated 
with fludarabine alone in the CALGB 9011 study.69 Patients 
assigned to receive fludarabine and rituximab had a higher 
incidence of CR and a significantly improved 2-year PFS and 
OS compared with patients receiving the purine analog alone. 
It is worth noting that 74% of patients treated with rituximab 
combined with fludarabine showed a higher incidence of grade 
3–4 neutropenia, although no difference in other hematological 
toxicity or infection development was noted.
The promising results obtained in the CALGB 9712 are 
in line with those of the Phase II study of the German CLL 
study group (GCLLSG).70 Fludarabine at the standard dose 
of 25 mg/m2 for four cycles associated with four infusions 
of rituximab led to an ORR of 87% with a CR rate of 33%. 
Similar responses were obtained in both untreated or previ-
ously treated patients enrolled in the study. This response 
rate was achieved after the administration of four courses of 
treatment and compares favorably with those reported with 
the most effective chemotherapy combinations in which six 
courses are generally administered,71–73 thus allowing the 
administration of a lower total dose of fludarabine.
One of the major risks when combining rituximab, which 
causes a prolonged depletion of B-cell lymphocytes, with 
fludarabine, which is responsible for profound and pro-
longed T-cells depletion, is the development of opportunistic 
infections. Both these studies showed that the frequency of 
infections was not increased after the immunochemotherapy 
treatment. Most of the opportunistic infections observed were 
of viral origin and this warrants an adequate prophylaxis 
against herpes virus.
Rituximab plus fludarabine  
and cyclophosphamide
Phase ii trials
The combination of fludarabine, cyclophosphamide and 
rituximab (FCR) was first evaluated at the MD Anderson 
Cancer Center in previously treated and untreated CLL 
patients.30,74 Fludarabine and cyclophosphamide (FC) were 
administered at doses of 25 and 250 mg/m2, respectively, for 
3 days. To prevent the risk of tumor lysis syndrome the first 
dose of rituximab was 375 mg/m2 increasing to 500 mg/m2 
from the second to the sixth doses.
In the 177 previously treated patients the ORR was 73%, 
25% of cases reached a CR and median time to progression of 
responding patients of 28 months.74 The results of this study 
revealed some important issues. Even if the comparability 
with previously reported Phase II studies is limited, the 
authors reported higher responses and CR rates and longer 
PFS with the combination immunochemotherapy compared 
with those reported for FC alone.
Furthermore previous treatment with FC does not have 
a detrimental effect on response to FCR, as in this group 
of patients CR and OR rates obtained were similar to those 
for the entire group and to those for patients treated with 
only alkylating agents. Number of responses observed in 
the fludarabine-refractory group of patients (6% CRs, 58% 
ORs) was lower, even though the results were comparable 
with those reached after salvage treatment with alemtuzumab 
in the same setting of patients.75,76
It should be emphasized that all six intended courses of 
treatment were administered to less than 50% of patients 
(46%). Dose reduction occurred in 25 cases,   myelosuppression 
being the primary reason for dose reduction. Grade 3–4 neu-
tropenia occurred in 62% of courses, and major infections 
were observed in 5% of courses (16% of patients).
An impressively high ORR together with a good quality 
of responses has been observed after FCR in first-line treat-
ment. Keating et al reported an ORR of 95% with 70% of 
CRs in 224 untreated patients.30 Notably, of the 207 patients 
evaluated at the end of treatment with flow-cytometry stud-
ies, 67% had less than 1% CD5 and CD19 co-expressing 
cells. This study underlined the importance of eradicating 
MRD, as there was a strong correlation between probability 
of relapse and responses as well as CD5/CD19 determined 
by flow-cytometry response.
Compared with the historical group of patients treated 
with FC, a higher incidence of myelosuppression with a 
grade 3–4 neutropenia was detected in 52% of courses, and 
in 38% after chemotherapy, alone even though the incidence 
of major infections was similar in 2.6% of courses.30 Time 
to progression and time to treatment failure survival were 
significantly better with FCR than with FC.
Recently Tam et al reported the update of the MD Anderson 
Cancer Center experience on 300 patients   receiving FCR OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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as initial therapy.27 The impressive clinical activity was 
confirmed by a CR rate of 72% and 42% of CR patients 
reaching PCR negativity. Six-year OS and failure-free sur-
vival were 77% and 51%, respectively, and median time to 
progression was 80 months. MRD negativity, determined by 
flow-cytometry and PCR, was correlated with superior time 
to progression (median 85 vs 49 months) and survival (84% 
vs 65%) at 6 years. Karyotypic abnormalities other than those 
involving chromosome 17 had no effect on CR or survival. 
In addition it should be noted that immunochemotherapy 
with FCR may overcome the adverse prognostic significance 
of del11q.77 The extended follow-up of patients permitted 
the evaluation of late toxicity during remission.27   Following 
completion of therapy, 19% of patients had persistent cytope-
nia lasting more than 3 months. Recurrent late cytopenia 
episodes occurred, predominantly during the first year, in 
28% of 245 patients; the risk of serious or opportunistic 
infection was 10% and 4% during the first and second years 
of remission, respectively.
Phase iii trials
The benefit of adding rituximab to FC has also been exam-
ined in prospective randomized trials in previously treated 
or untreated patients.
The REACH trial was designed to directly compare FCR 
with FC alone in patients with previously treated CLL.28 The 
findings of this multicenter randomized trial including 552 
patients supported the results reported in Phase II single-
institution studies.74,78 In the group of patients randomized to 
receive the monoclonal antibody, significant improvement of 
ORR, CR and PFS was observed. Of note, both Binet stage 
B and C patients benefited from FCR as did patients with 
poor prognostic features such as del11q, unmutated IgVH 
and positive ZAP-70. Overall survival was not significantly 
improved but follow-up was relatively short and a post-trial 
crossover to rituximab had occurred. As reported in other 
studies, patients treated with FCR showed a higher rate on 
grade 3–4 neutropenia even if there was no increase in overall 
or severe infections.
The superiority of FCR over FC was also confirmed in the 
877 untreated patients enrolled in the randomized GCLLSG 
(CLL8).79 FCR induced a higher ORR than FC (95 vs 88%), 
more CRs (44% vs 22%; P , 0.001) and longer median PFS 
(51.8 months vs 32.8 months). It should be emphasized that 
this is the first randomized study to demonstrate a superior-
ity in OS (at 37.7 months 84.1% vs 79.0%) between the two 
treatment arms, even if this superiority was demonstrated 
only in Binet stages A and B patients.31
The importance of eradicating MRD was confirmed by 
the GCLLSG CLL8 trial, which demonstrated that median 
PFS depended on the ability to eradicate MRD in the peripheral 
blood.
Hematological toxicity was higher in the FCR group of 
patients, even though the mean number of courses delivered 
in the two groups of patients was similar, 5.2 in the FCR arm 
  versus 4.8 courses in the FC, with a total median   cumulative 
dose of chemotherapy applied per patient. No statistically sig-
nificant difference between the two treatments was observed.
The results of Phase III trials of rituximab combined with 
fludarabine alone (FR) or with cyclophosphamide (FCR) are 
summarized in Table 2.
In a randomized study of untreated patients, FCR was 
shown to be more effective and to have a better safety profile 
compared with the same regimen combined with alemtu-
zumab (FCCam). This study was closed prematurely because 
of excessive toxicity observed in the FCCam arm.80
The efficacy of the FCR combination as well as the 
possible associated toxicities led to the investigation of two 
different regimens in which the three drugs were combined 
at different dosages or were administered sequentially with 
the aim of reducing toxicity while preserving efficacy.81,82
Foon et al tested a reduced version of FCR (FCR-Lite) 
in untreated patients.81 Fludarabine was dose reduced to 
20 mg/m2 and cyclophosphamide to 150 mg/m2 while ritux-
imab was increased to 500 mg/m2 on days 1 and 14 of a 
28-day cycle and was also given as consolidation treatment 
until relapse. All the 48 assessed patients responded to treat-
ment, 38 patients reaching a CR (79%) and 37 showing a 
negative flow-cytometry. Similar to other studies with FCR, 
the high-risk feature of del17p was associated with a poor 
response. None of the patients who entered CR showed 
disease progression after a median of 22.3 months. Even if 
the reported follow-up is rather short to enable the outcome 
to be compared with other FCR studies, this study demon-
strated that a high ORR can be reached with a reduced dose 
of chemotherapy, clearly showing a major reduction in grade 
3–4 neutropenia (13% of cycles).
At the Memorial Sloan-Kettering Cancer Center, flu-
darabine, cyclophosphamide and rituximab were sequen-
tially administered.82 Initially patients received fludarabine 
for 6 cycles at the standard dose of 25 mg/m2 for 5 days, 
thereafter cyclophosphamide was given as consolidation 
treatment for 3 cycles at the dose of 3000 mg/m2 every 3 
weeks followed by consolidation with rituximab infusions 
once a week for four weeks. The sequential regimen showed 
significant efficacy, with an ORR of 89% including 61% of OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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CRs. The majority of the enrolled patients presented a high-
risk disease according to stage and prognostic features. The 
addition of rituximab improved the CR rate and the quality of 
responses: MRD eradication determined by flow-cytometry 
or by patient/tumor-specific nucleotide primers PCR was 
achieved in 56% and 33% of cases, respectively.
Rituximab in combination  
with other purine analogs
Pentostatin, among purine analogs active in CLL, appears 
to be less myelosuppressive than fludarabine. The degree 
of myelosuppression seems to be favorable, even when 
pentostatin is combined with cyclophosphamide, compared 
with fludarabine-based combinations.83 Several studies have 
investigated the efficacy of the combination pentostatin, 
cyclophosphamide and rituximab (PCR) either in previously 
treated or untreated CLL patients (Table 3).
In a cohort of 32 previously treated CLL patients, 
Lamanna et al reported an ORR of 75%, including 25% of 
CRs, with a median response duration of 25 months and 
a median time to treatment failure of 40 months.84 These 
authors compared their results with those obtained at the MD 
Anderson Cancer Center after FCR treatment in the same 
setting of patients.74 Even if there are inherent limitations 
in this comparison, they noted that responses were virtually 
identical in the two treatment regimens and median survival 
of all patients was comparable. The frequency of grade 3–4 
neutropenia and infectious complications including fever of 
unknown origin reported after PCR were inferior to those 
reported after FCR. Moreover, PCR was better tolerated, as 
a high proportion of patients received all planned therapy at 
full dose (72% vs 38% with FCR).
The efficacy of PCR, with pentostatin administered at the 
dose of 2 mg/m2, has also been documented in 64 untreated 
patients.85 In a subsequent study Shanafelt et al reported that 
PCR can be safely administered to older patients ($70 years) 
and those with modestly decreased creatinine clearance.86 
These results appear to contrast with the tolerability of the 
FCR regimen: in the PCR study older patients were as likely 
as younger patients to complete the intended 6 cycles and to 
achieve CR (41 vs 39%) or PR (52 vs 44%) without excess 
of grade 3–4 toxicity.
To find out whether results obtained with immunochemo-
therapy regimens in academic centers are reproducible in the 
community setting, Reynolds et al carried out a Phase III ran-
domized trial to compare FCR and PCR in previously untreated 
or minimally treated B-cell CLL.87 The primary endpoint, 
incidence of grade 3–4 infections, was similar in the two arms. 
Only 50% of patients in both arms completed therapy, resulting 
in low OR rates that were not statistically different between the 
two treatment groups. The reason for not completing therapy 
could be related to the choice of drug dosages. Pentostatin was 
administered at the higher dosage of 4 mg/m2 while in the FCR 
regimen patients received fludarabine 20 mg/m2 for 5 days and 
cyclophosphamide at 600 mg/m2 in 1 day.
To improve tolerability while preserving efficacy, the 
higher dosage of pentostatin (4 mg/m2) has also been used 
in association with rituximab, without cyclophosphamide, in 
first-line treatment.88 This combination led to lower OR (76%) 
and CR rates (27%) as well as shorter treatment-free survival 
compared with the PCR regimen. These results support previ-
ous findings on the importance of adding cyclophosphamide 
to purine analogs and rituximab to improve response rates 
and prolong PFS.
There is only one published study on the combination of 
rituximab and intravenous cladribine (RC) with or without 
cyclophosphamide in refractory and relapsed CLL patients. 
The objective response observed (78%) was in line with 
the other immunochemotherapy regimens and superior to 
cladribine used alone or in combination with cyclophos-
phamide. As observed when combining rituximab with 
fludarabine, the addition of the monoclonal antibody to 
cladribine did not confer a higher infectious rate. Even though 
this is a small series of patients, the authors noted that the 
response ratio was similar in patients treated with or without 
cyclophosphamide.89
The efficacy on CLL and SLL of cladribine administered 
subcutaneously with rituximab has been recently reported.90 
Considering that four courses of therapy were administered and 
that 38% of patients had been previously treated, an impressive 
50% CRs (54% untreated; 44% pretreated) was reported.
Rituximab in combination with 
other chemotherapeutic agents
The results of the studies are summarized in Table 4.
Rituximab plus bendamustine
Recently the particular mechanism of action of bendamus-
tine, an alkylating agent with additional properties of a 
purine analog, has reawakened interest in this drug that has 
been extensively studied in indolent NHL and in CLL.91 
The preclinical observations demonstrating synergistic 
pro-apoptotic effects of bendamustine and rituximab (BR) 
supported clinical studies combining the two agents.
The GCLLSG initiated the CLL2M phase II study to 
investigate the combination of bendamustine at 70 mg/m2 OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Rituximab in chronic lymphocytic leukemia
on two consecutive days plus rituximab on day 1 at a dose 
of 375 mg/m2 for the first course and 500 mg/m2 during sub-
sequent cycles in 81 relapsed CLL patients.92 BR treatment 
was administered every 28 days for up to six courses. In the 
62 patients assessable for response, the ORR was 77.4% with 
a CR rate of 14.5% of patients. Of note is that a high ORR 
(92%) was observed among patients with del11q. Major but 
tolerable treatment toxicities were myelosuppression and 
infections. Grade 3–4 infections were documented in 5% of 
all given cycles.
Based on these interesting results BR was considered 
in first-line treatment in a multicenter Phase II study of 
the GCLLSG.93 Preliminary results on 117 CLL patients 
showed an ORR of 90.9% with a CR in 32.7% of cases. After 
18 months 75.8% of the patients were still in remission with 
a median PFS not reached. Grade 3–4 infections occurred in 
5% of all administered courses. As in the previously treated 
patients, BR confirmed its efficacy even among patients with 
adverse prognostic features such as del11q and unmutated 
IgVH status, leading to ORR of 90.5% and 88.9%, respec-
tively. Patients with del17p achieved only PRs (42.9%). The 
GCLLSG is presently investigating the efficacy of BR in 
comparison with fludarabine-based immunochemotherapy 
(FCR) as first-line treatment of CLL within a randomized 
Phase III trial (CLL10 protocol).
In a recently published retrospective trial, Weide et al 
evaluated 39 elderly patients with relapsed or refractory 
CLL who were treated with bendamustine, mitoxantrone and 
rituximab (BMR).94 Treatment consisted of bendamustine 
90 mg/m2 on days 1 to 2, mitoxantrone 6 mg/m2 on day 1 
and rituximab 375 mg/m2 on days 8, 15, 22 and 29. ORR was 
92% (10% CR, 82% PR), with many patients receiving only 
a single cycle of immunochemotherapy. Median time to next 
CLL therapy was 13 months (0–69). Therapy was well toler-
ated, with two observed therapy-associated hospitalizations. 
A reversible grade 3–4 hematological toxicity was seen in 
30 patients (77%).
Rituximab plus chlorambucil
Despite the increasing use of fludarabine-containing regimens 
and more recently FCR, chlorambucil remains a first-line 
treatment option, particularly for elderly patients and those 
with co-morbidities.16 However, rates of CR obtained with the 
alkylating agents are relatively low (up to 7%) as are overall 
responses (approximately 65%). In the United   Kingdom (UK) 
a phase II study is ongoing designed with the aim of assessing 
the feasibility of adding rituximab to   chlorambucil in order 
to improve outcomes.95 Treatment consisted of rituximab 
(375 mg/m2 day 1 in the first cycle, 500 mg/m2 in cycles 
2–6) plus chlorambucil (10 mg/m2 days 1–7) repeated every 
28 days for six cycles. A further six cycles of chlorambucil 
alone was permitted in patients with continuing clinical 
response at six cycles. The interim analysis on 50 patients 
showed an ORR of 84%, which is 17.3% higher than in the 
well-matched subset of patients from the UK LRF CLL4 study 
treated with chlorambucil in monotherapy.20  The high median 
age of patients entered in the study and the good tolerance, 
even in older patients, suggest that this combination treatment 
may be considered in those patients who cannot tolerate a 
more intensive regimen.
Rituximab plus fludarabine, 
cyclophosphamide, and mitoxantrone
The combination fludarabine, cyclophosphamide, and mitox-
antrone (FCM) has been extensively, used demonstrating a 
high effectiveness in CLL patients both previously untreated 
and treated.21,96,97 The next logical development of this 
treatment program was to investigate the role of rituximab 
addition (FCM-R). Hillmen et al reported the results of a 
small Phase II randomized trial which attempted to compare 
FCM with FCM-R in pretreated patients. CR rate was higher 
in patients receiving the monoclonal antibody (43%) even 
though the small number of patients did not allow statisti-
cally valid conclusions. Once again, this trial demonstrated 
that the addition of the monoclonal antibody did not increase 
toxicity, as the rate of serious adverse events was similar in 
the two treatment arms.98
Bosch et al treated 72 naïve CLL patients with this 
combination, obtaining a 93% ORR including 82% CRs, 
of which 46% were MRD negative, using multiparametric 
flow-cytometry. Results of the FCM clinical study were 
retrospectively compared with those of the immunochemo-
therapeutic regimen. Although the ORR rate was similar 
with the two treatment programs, the proportions of CRs and 
MRD negativity were significantly higher in patients receiv-
ing rituximab.99 Variables associated with a lower CR, even 
with immunochemotherapy, included beta2-microglobulin 
and del17p. Severe neutropenia and infections were higher 
in patients treated with FCM-R even when comparing only 
the group of younger patients (age ,65 years).
The same regimen with a higher dosage of rituximab 
(FCM-R) was investigated by Faderl et al in a pilot study 
of 30 untreated CLL patients in an attempt not to compare 
immunochemotherapy with chemotherapy, but to evaluate 
whether mitoxantrone addition to FCR provided any sub-
stantial benefit.100 The authors concluded that compared to OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
238
Tedeschi et al
FCR the addition of mitoxantrone does not seem to give more 
benefit when looking at clinical flow-cytometry or   molecular 
responses. Further follow-up is required to assess the   benefit 
in terms of time to treatment failure. The frequency of 
severe neutropenia was similar between FCM-R and FCR 
and in general the addition of mitoxantrone was associated 
with a greater myelosuppressive effect, since every patient 
received hematopoietic growth factor. The small number of 
patients enrolled in this study does not allow conclusions 
to be drawn on the influence of mitoxantrone on particular 
subgroups of patients.
Rituximab plus fludarabine, oxaliplatin, 
and cytarabine
Rituximab was also combined with fludarabine, oxaliplatin, 
and cytarabine (OFAR) in a Phase I/II dose-finding study for 
patients with fludarabine-refractory CLL.101 After a median 
number of two courses, ORR achieved in this high-risk 
group of patients was 33%, with responses observed only in 
cases treated with the higher oxaliplatin dosage of 25 mg/m2. 
Responses were high, 33%, even in the subset of patients car-
rying the 17p deletion. The superiority of OFAR compared 
with other cisplatin-based therapies could be attributed to 
the substitution of oxaliplatin for cisplatin, the consider-
able dose of cytarabine administered and the addition of the 
monoclonal anti-CD20 antibody.102,103 A subsequent study 
(OFAR2) with rituximab in association with the same che-
motherapeutic agents, administered at different dose levels 
(higher oxaliplatin, lower cytarabine dosages), confirmed 
the high efficacy of the combination in 52 refractory CLL 
patients. A response was achieved in 63% of patients, with 
a high antileukemic activity in patients with del17p; median 
survival duration was 21 months.104
Rituximab in combination  
with monoclonal antibodies
The rationale of combination treatment with monoclonal 
antibodies is based on: suboptimal efficacy of single-agent 
monoclonal antibody therapy, different molecular targets of 
the antibodies and different mechanism of action.
Rituximab and alemtuzumab
Alemtuzumab is a monoclonal humanized antibody specific 
for the CD52 antigen which is expressed at high levels in CLL 
cells and is active in initial and salvage therapy.105 Treatment 
with alemtuzumab is warranted in patients with del17p and/or 
p53 mutations, both of which have been associated with 
resistance to most other available CLL treatment agents.
A pilot study to evaluate efficacy and tolerability of the 
combination of rituximab and alemtuzumab was performed in 
12 heavily pretreated patients failing purine analogs therapy. 
Patients were treated in three different cohorts: rituximab 
375 mg/m2 was administered weekly for 4 weeks while alem-
tuzumab dosage was escalated in the different cohorts accord-
ing to toxicity (3 mg, 10 mg, 30 mg, respectively, 3 times a 
week for 4 weeks).106 Although only one patient achieved an 
objective response, the combination of the two monoclonal 
antibodies was shown to be safe as no significant myelosup-
pression was noted and none of the patients developed an 
opportunistic infection. Cytomegalovirus (CMV) reactivation 
was not detected in this trial but it should be emphasized that 
CMV antigenemia was not routinely performed. In an MD 
Anderson Cancer Center trial the administration with ritux-
imab of the higher dosage of alemtuzumab, 30 mg iv 3 times 
a week, led to a higher response rate with at least one episode 
of infection in 52% of treated patients,107 although none of the 
infections was fatal. Because a wide range of diagnoses was 
included in this series, it is difficult to draw any firm conclusion 
on whether the combination of rituximab and alemtuzumab 
has any advantage over single-agent monoclonal antibody 
therapy. In a more recent study, on only CLL patients, the same 
authors reported on the efficacy of the combination of the two 
monoclonal antibodies administered at a higher dosages with a 
different schedule.108 ORR (53%) and time to treatment failure 
were similar to those in the previous study, with a trend toward 
a higher CR rate (18%). Documented infections occurred in 
28% of patients but even in this study no fatal infections or 
opportunistic infections were recorded.
The interest in this combination of two monoclonal 
antibodies led to its efficacy being investigated as front-line 
treatment. Frankfurt et al reported the results of subcutaneous 
alemtuzumab administration in 20 previously untreated and 
symptomatic patients.109 A high CR rate was achieved (40%), 
including all patients with del11q abnormality. Furthermore 
at the completion of therapy 70% of patients had no evidence 
of MRD by flow-cytometry.
Zent et al used the combination in untreated asymp-
tomatic patients who had at least one marker of high-risk 
disease: del17p, del11q or combination of unmutated IgVH 
and CD38+/ZAP-70+.110
In both these first-line treatment studies, patients with 
CMV reactivation were described (30% and 10%, respec-
tively). A low incidence of infections was reported: one 
patient in the first study developed CMV disease with full 
recovery after foscarnet, one patient in the second study was 
hospitalized after neutropenic fever.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Although the combination of the two monoclonal 
  antibodies was demonstrated to be effective, with a low rate 
of severe infections, the profound immunosuppression docu-
mented warrants further investigation in particular subsets of 
patients, providing careful monitoring of complications.
One possible way to further increase the efficacy observed 
with FCR might be the addition of the combination of another 
monoclonal antibody targeting a different antigen.
At the MD Anderson Cancer Center, alemtuzumab 30 mg 
iv on days 1, 3, and 5 was added to FCR (CFAR regimen) 
in a first Phase II study with 79 refractory patients. An ORR 
of 65% and a CR rate of 24% were observed, patients who 
obtained CR showed a negative by flow-cytometry MRD.111 
As for most salvage treatments CFAR was more active in 
patients who were sensitive to their previous fludarabine 
regimen (ORR 74%, CR 36%) than in fludarabine-refractory 
patients (ORR 49%, CR 6%). It should be emphasized that 
the regimen was shown to be effective in 44% of patients 
presenting with 17p deletion. The incidences of major infec-
tions (11%), minor infections (28%) and fever of unknown 
origin (36%) were similar to those observed with FCR in 
the relapsed setting.
Given these promising results, this combination was sub-
sequently administered as first-line treatment in patients with 
high-risk features determined as either 17p deletion and/or 
a high level of beta2-microglobulin (twice the upper normal 
level).112 ORR achieved in the whole population was 92%, 
with 70% of CRs. A CR of 57% was observed in patients 
with del17p, with an ORR of 78%. Results and toxicities 
were compared
The addition of alemtuzumab conferred a higher CR 
rate and bone marrow MRD negativity in the same group 
of high-risk patients who received FCR only. After the 
CFAR regimen a higher rate of myelosuppression and CMV 
reactivation were observed. Incidence of other infections 
was similar. Treatment discontinuation was observed more 
often in patients receiving CFAR. The short follow-up of 
24 months did not reveal differences in time to progression 
and OS between CFAR and the historical FCR control group. 
Longer follow-up will help to determine the role of CFAR 
in high-risk patients, although the response rate observed in 
these patients is the highest reported to date.
Rituximab and lumiliximab
Lumiliximab, a monoclonal antibody that binds specifically 
to CD23, has been tested in association with FCR in 31 
refractory/relapsed patients.113 Although the OR the results 
observed in this study are very similar to the others reported 
with FCR alone, the addition of lumiliximab increased CR 
twofold (65%). Importantly, the addition of the second 
monoclonal antibody did not increase toxicity. A large global 
randomized study comparing FCR with FCR plus lumilix-
imab in previously treated patients is ongoing.
Rituximab in combination with 
nonchemotherapeutic agents
Rituximab plus steroids
High-dose methylprednisolone (HDMP) is an established 
treatment in refractory CLL and can induce responses both 
in bulky disease and p53 mutation.114,115 In preclinical studies 
rituximab was show to act synergistically with methylpred-
nisolone to induce apoptosis of CLL cells, particularly in the 
presence of nurse-like cells.
Castro et al were the first to describe the combination of 
HDMP 1 g/m2 for 5 days with rituximab in refractory patients, 
reporting excellent response rates (93%) and tolerability.116 
Similar results, summarized in Table 5, were observed in 
the Mayo Clinic retrospective study and in smaller series of 
heavily pretreated patients (ORR 93% to 75%, median PFS 
or duration of response 7 to 14 months).117–119 In all series a 
high activity of the combination was reported in patients with 
aggressive disease features including those with del17p and/
or bulky adenopathy, although in all studies a significantly 
high rate of infection (21.4% to 29%) was observed.
Castro et al conducted a study to evaluate dosing and 
toxicity of the HDMP and rituximab combination in chemo-
therapy-naïve patients.120 Patients received HDMP 1 g/m2 for 
3 days; rituximab was administered in the first group at the 
dosage of 375 mg/m2 for 12 doses and in the second group 
at a higher dosage of 750 mg/m2 for 9 doses. ORR was 96% 
with 32% of CRs, 8% of which were MRD negative. It has 
to be emphasized that all patients .70 years responded to 
treatment and all cases with del11q and del17p achieved an 
objective response. No statistical difference in response was 
observed when patients were categorized according to the 
rituximab dosage. Median PFS and treatment-free survival 
were 30.5 and 33.3 months, respectively, and for CR patients 
median PFS was 40.3 months.
Rituximab and granulocyte-macrophage 
colony-stimulating factor
Although the synergistic effect of rituximab with chemother-
apeutic agents is well known the toxicity of immunochemo-
therapeutic regimens remains a limitation. The availability 
of agents that may enhance rituximab’s efficacy without the OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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myelosuppressive effects of chemotherapy has led to the 
investigation of cytokine partners.
As the lower density of CD20 antigen in CLL is consid-
ered one of the most important factors responsible for reduced 
rituximab activity, one approach to enhance responses could 
be the use of cytokines, such as granulocyte-macrophage 
colony-stimulating factor (GM-CSF) or interleukin-4, to 
upregulate CD20.121
The rationale for using GM-CSF in combination with 
rituximab is based on the observation of   Venugopal et al that 
CLL patients exposed in vitro to GM-CSF have increased 
expression of surface CD20, potentially making them a 
better target for rituximab.121 Furthermore the addition of 
GM-CSF in vitro enhances rituximab-induced ADCC against 
CLL cells, stimulating granulocyte and macrophage natural 
cytotoxicity.122
A phase II study conducted at the MD Anderson Cancer 
Center demonstrated the efficacy of the combination of ritux-
imab at the standard dose of 375 mg/m2 weekly for 4 weeks 
combined with GM-CSF 250 µg subcutaneously 3 times a 
week for 8 weeks.123 The ORR observed in the 118 patients 
treated was 65% with 9% of CRs, 10% of nodular PRs and 
53% PRs. The results suggested an improvement in response 
rate with the combination treatment over rituximab in mono-
therapy either in untreated or recurrent disease patients. The 
most common toxicity observed was mild erythema at the 
site of GM-CSF injection; six episodes of major infections 
were documented.
Considering the favorable results obtained with GM-CSF 
plus rituximab and considering the severe   myelosuppressive 
effects observed after immunochemotherapy regimens, 
GM-CSF could play a role as a myeloid growth factor and 
in addition synergize with rituximab.
Ferrajoli et al recently reported the preliminary data of 
GM-CSF given in combination with FCR regimen in front-
line treatment.124 The study confirmed the achievement of 
a high ORR (100%) and CR (72%) rates. Of note, 85% 
of patients treated with this combination completed all 6 
planned courses and only two patients (4%) received fewer 
than four courses.
Rituximab plus lenalidomide
Lenalidomide is an immunomodulatory drug that is a more 
potent analog of thalidomide. In patients with relapsed/refrac-
tory CLL, treatment with single-agent lenalidomide induced 
an ORR of 32% to 47% when used as monotherapy.125,126 The 
combination of rituximab and lenalidomide was investigated 
at the MD Anderson Cancer Center based on the possible 
enhanced activity of rituximab induced by lenalidomide 
which stimulates natural killer (NK) cell proliferation.127
Patients were treated with rituximab (375 mg/m2) iv 
on days 1, 8, 15 and 22 of cycle 1, and then once every 4 
Table 5 Rituximab in combination with high-dose steroids
Authors No. 
evaluable pts
Disease 
status
Regimen Response Follow-up
Castro et al116 14 Pretreated HDMP 1 g/m2/d iv for 5 days plus
rituximab 375 mg/m2 iv d 1, 8,  
15, 22 every 4 weeks
13 (93%) OR
5 (36%) CR
Median TTP 15 m
Median TFS: 22 m
Quinn et al117 12 Pretreated Rituximab (dose not stated) plus
HDMP 1 g/m2/d iv for 5 days 
or HDD 40 mg/d iv for 4 days every 4 weeks
9 (75%) OR
1 (8%) CR
Median 
DoR: 14 m
Bowen et al118 37 Pretreated HDMP 1 g/m2/d iv for 5 days plus
rituximab 375 mg/m2 iv d 1, 8, 15,  
22 every 4 weeks
29 (78%) OR
8 (22%) CR
Median PFS: 1 y
3 y survival: 41,3%
Dungarwalla et al119 14 Pretreated HDMP 1 g/m2/d iv for 5 days plus
rituximab 375 mg/m2 iv d 1 every 28 days
13 (93%) OR
2 (14%) CR
Median PFS: 7 m
Median OS: 20 m
Castro et al120 28 Untreated HDMP 1 g/m2 iv d 1–3 for  
3 courses plus
Group 1: rituximab 375 mg/m2  
iv 12 doses
Group 2: rituximab 750 mg/m2  
iv 9 doses
27 (96%) OR
9 (32%) CR
Median FU 3 y: OS 96%
Median PFS 30.5 m
Median TFS 33.3 m
Abbreviations: pts, patients; HDMP, high-dose methylprednisolone; HDD, high-dose dexamethasone; iv, intravenous; d, days; y, year; OR, overall response; CR, complete 
response; TTP, time to progression; PFS, progression-free survival; TFS, treatment-free survival; DoR, duration of response; FU, follow-up.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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weeks during cycles 3 to 12. Lenalidomide was given orally 
at the dose of 10 mg/day starting on day 9 of cycle 1 and 
continued daily for 12 cycles. Recently the results on 37 
refractory relapsed patients treated with at least six courses 
have been reported.128 The ORR (68%) was superior to that 
with single-agent lenalidomide despite all patients   having 
received prior rituximab. Furthermore no differences in 
responses among the different prognostic groups were 
observed. Interestingly, the percentage of CD19+CD20+ 
B-cells decreased, and the percentages of CD4+ T, CD8+ T, 
CD4+CD25hiCD127– regulatory T and CD3-CD16+CD56+ 
NK cells significantly increased.
Rituximab in maintenance therapy
Rituximab is an attractive candidate for maintenance 
therapy due to a favorable combined efficacy and safety 
profile, thus allowing extended therapy to improve out-
come without compromising quality of life. In low-grade 
NHL, rituximab maintenance treatment clearly suggests 
an improvement in outcome following responses obtained 
with initial rituximab monotherapy or either chemotherapy 
or immunochemotherapy.129–131
Hainsworth et al administered consolidation treat-
ment with rituximab in four weekly courses, at 6-month 
intervals, for 2 years in those CLL patients responding or 
showing a stable disease after initial front-line rituximab 
  monotherapy.59 Consolidation treatment increased ORR from 
51% to 58%, and CR rate from 4% to 9%. The median PFS 
at the time of reporting was 18.6 months with a projected 
1-year and 2-year PFS of 62% and 49%, respectively. Long-
term toxicity during rituximab maintenance therapy was 
reported to be mild.
In a similar study rituximab consolidation was evaluated 
in 28 patients in CR or PR with positive flow-cytometric 
MRD after fludarabine treatment.132 Rituximab was initially 
administered for four weekly doses, then MRD-positive 
patients received 4 monthly cycles of rituximab at 375 mg/m2 
followed by 12 monthly doses at 150 mg/m2. Postinduction 
therapy significantly increased response duration compared 
with controls (87% vs 32% at 5 years). Updated results of 
this study, recently reported, confirmed the long PFS of 
consolidated patients from the end of induction treatment 
(40% at 9 years).133
A response-adjusted and flexible low-dose rituximab 
maintenance regimen was designed for relapsed CLL patients 
who achieved a partial or minimal response to prior therapy 
with rituximab.134 Patients received the monoclonal antibody 
at the dosage of 100 mg on a 4-week schedule, if disease 
progression occurred during the interval between treatments 
was reduced or 500 mg of rituximab was given every 2 to 
4 weeks. Maintenance therapy was successfully carried out 
in $6 months in 7 of the 12 enrolled patients with mild 
long-term toxicity. In three cases partial remission or minor 
response was maintained for relatively long periods (up to   
42 months).
Conclusion
In the past 20 years considerable progress had been made in 
molecular and cellular biology, and prognosis and treatment 
of patients with CLL. These achievements have provided the 
basis for the development of innovative and more effective 
therapies in this disease. Two reports135,136 recently published 
demonstrated, by comparing cohorts of patients from the 
1980s and the 2000s, that survival in CLL patients had signifi-
cantly improved. These data suggest that improved therapies, 
particularly in younger patients, might improve OS.
The introduction of rituximab has revolutionized the 
treatment of lymphoproliferative disorders. In CLL ritux-
imab monotherapy has limited activity in refractory/relapsed 
patients, with responses being generally inferior to those seen 
in NHL. Although increasing dose intensity and frequency 
leads to higher response rates, even in first-line treatment, 
responses are almost always partial and of short duration. 
Furthermore the high dosages used are not feasible in routine 
clinical practice.
On the basis of preclinical evidence of the synergism 
between rituximab and fludarabine, rituximab has been 
incorporated into fludarabine-based regimens. Concurrent 
fludarabine and rituximab has been shown to increase ORR, 
CR and PFS but not long-term survival benefit. A further 
amelioration of the quality of responses has been achieved 
with the FCR. The improvement in PFS resulted directly 
from an improved ability to eradicate MRD, highlighting 
the importance of MRD eradication. The CLL8 German ran-
domized trial is the first study demonstrating the superiority 
of the FCR arm over the comparator (FC) arm in prolonging 
OS. Based on the demonstrated benefit of FCR treatment, 
the US Food and Drug Administration has recently approved 
the new indication of this anti-CD20 monoclonal antibody 
as treatment of naïve or relapsed CLL, in combination with 
standard cytotoxic chemotherapy consisting of fludarabine 
and cyclophosphamide. Despite the demonstrated efficacy 
of FCR, important issues must still be addressed. Should 
FCR be considered the ‘standard’ care for all patients? OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Selection of the most appropriate initial therapy in CLL 
must be based primarily on patient characteristics such 
as age, performance status, co-morbidities and biological 
disease characteristics. Although the addition of rituximab 
to FC improved outcome in patients with p53 mutation or 
del17p, results with this combination treatment are still 
unsatisfactory so that alternative treatments such as alem-
tuzumab or investigational therapies should be considered. 
As of now, FCR should be considered the standard care in 
young, fit patients in which the reasonable goal of treat-
ment is CR, possibly MRD-negative CR. Although FCR 
toxicity is manageable and infections are similar to those 
observed after chemotherapy alone, the high rate of pro-
found myelosuppression, persisting in some cases after the 
end of therapy, warrants adequate monitoring prophylaxis 
and high standard of care.
Management decisions can be different in elderly patients 
with comorbidities, as FCR may be poorly tolerated. This 
group of patients may benefit from other combination regi-
mens including rituximab (eg, PCR, BR), or alternatively 
first-line alemtuzumab treatment if severe CLL-related 
pancytopenia is present.
A large randomized multicenter study showed that 
results obtained after FCR treatment in clinical trials 
are not reproducible in the community setting where the 
majority of patients are treated. Furthermore what has 
not been answered in a randomized fashion is whether 
FCR is superior, with a similar tolerability, to other 
combination regimens such as PCR, FCR-Lite, BR, and   
R-FCM.
Even if high CR rates with eradication of MRD have been 
obtained with FCR, a proportion of patients still show a poor 
outcome. To overcome resistance in the high-risk group of 
patients new treatment strategies are under investigation. 
Preliminary results have shown that the FCR regimen with 
the addition of alemtuzumab is effective in treating high-
risk patients in first-line treatment. Opportunistic infections 
related to concomitant depletion of T- and B-cell lymphocytes 
when alemtuzumab and rituximab are administered should be 
strictly monitored. Longer follow-up of the study is needed in 
order to assess if an advantage in PFS and/or OS is recorded in   
poor-risk CLL.
Different strategies with nonchemotherapeutic agents 
are under investigation. The combination of rituximab and 
lenalidomide has been shown to be more effective than 
lenalidomide alone in relapsed/refractory patients, even 
in cases showing adverse prognostic features and bulky 
disease.
Additional studies based on biological stratification with 
an adequate follow-up are warranted in order to assess the 
impact of rituximab combined with new compounds.
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